Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Aug:254:8-11.
doi: 10.1016/j.psychres.2017.04.025. Epub 2017 Apr 14.

Genome-wide association study of treatment response to venlafaxine XR in generalized anxiety disorder

Jeesun Jung  1 , Elisabeth A Tawa  2 , Christine Muench  2 , Allison D Rosen  2 , Karl Rickels  3 , Falk W Lohoff  4
Affiliations

Genome-wide association study of treatment response to venlafaxine XR in generalized anxiety disorder

Jeesun Jung et al. Psychiatry Res. 2017 Aug.

Abstract

We conducted the first genome-wide association study (GWAS) in Generalized Anxiety Disorder (GAD) to identify potential predictors of venlafaxine XR treatment outcome. Ninety-eight European American patients participated in a venlafaxine XR clinical trial for GAD, with Hamilton Anxiety Scale (HAM-A) response/remission at 24 weeks as the primary outcome measure. All participants were genotyped with the Illumina PsychChip, and 266,820 common single nucleotide polymorphisms (SNPs) were analyzed. Although no SNPs reached genome-wide significance, 8 SNPs were marginally associated with treatment response/remission and HAM-A reduction at week 12 and 24 (p<0.00001). Several identified genes may indicate markers crossing neuropsychiatric diagnostic categories.

Trial registration: ClinicalTrials.gov NCT00183274.

Keywords: Generalized anxiety disorder; Pharmacogenetics; Venlafaxine XR.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest

The authors declare no conflict of interest.

Similar articles

See all similar articles

Cited by

References

    1. Anacker C, Zunszain PA, Cattaneo A, Carvalho LA, Garabedian MJ, Thuret S, Price J, Pariante CM. Antidepressants increase human hippocampal neurogenesis by activating the glucocorticoid receptor. Molecular psychiatry. 2011;16:738–750. - PMC - PubMed
    1. Baldwin DS, Nair RV. Escitalopram in the treatment of generalized anxiety disorder. Expert review of neurotherapeutics. 2005;5:443–449. - PubMed
    1. Cougle JR, Keough ME, Riccardi CJ, Sachs-Ericsson N. Anxiety disorders and suicidality in the National Comorbidity Survey-Replication. Journal of psychiatric research. 2009;43:825–829. - PubMed
    1. Gelenberg AJ, Lydiard RB, Rudolph RL, Aguiar L, Haskins JT, Salinas E. Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trial. Jama. 2000;283:3082–3088. - PubMed
    1. Grant BF, Hasin DS, Stinson FS, Dawson DA, June Ruan W, Goldstein RB, Smith SM, Saha TD, Huang B. Prevalence, correlates, co-morbidity, and comparative disability of DSM-IV generalized anxiety disorder in the USA: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Psychological medicine. 2005;35:1747–1759. - PubMed

MeSH terms

Substances

Associated data